PMID- 36217375 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230422 IS - 1177-889X (Print) IS - 1177-889X (Electronic) IS - 1177-889X (Linking) VI - 16 DP - 2022 TI - Patient-Reported Barriers to Adherence Among ACEI/ARB Users from a Motivational Interviewing Telephonic Intervention. PG - 2739-2748 LID - 10.2147/PPA.S360461 [doi] AB - PURPOSE: Hypertension is a common comorbidity among type 2 diabetes mellitus (T2DM) patients, which increases the risk of cardiovascular diseases. Despite the proven benefit of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in this population, poor medication adherence is prevalent, resulting in higher complications and mortality rate. Motivational interviewing (MoI) has demonstrated effectiveness in improving medication adherence and identifying barriers. This study aimed to assess and identify patient-reported barriers to adherence to ACEI/ARB from an MoI telephonic intervention conducted by student pharmacist interns. PATIENTS AND METHODS: This retrospective study was conducted within an MoI intervention customized by past ACEI/ARB adherence trajectories for nonadherent patients with T2DM and hypertension enrolled in a Medicare Advantage Plan. Adherence barriers were extracted from the interviewers' notes by two independent researchers. Descriptive analysis was performed to summarize the overall frequency of barriers as well as across trajectory groups, identified from the initial and follow-up calls. RESULTS: In total, 247 patients received the initial MoI call from which 41% did not communicate any barrier for ACEI/ARB use despite having low adherence. About 59% of the patients reported at least one barrier during the initial call. The most common barriers included forgetfulness, discontinuation by physicians, side effects, multiple comorbidities, polypharmacy, lack of knowledge about disease/medication, and cost issues. The follow-up calls helped with uncovering at least one new barrier for 28 patients who previously communicated a different issue with their medication during the first call. Additionally, 18 patients with initial denial for having any barrier to adherence reported at least one barrier throughout the follow-up calls. CONCLUSION: This study summarized patient-reported barriers to ACEI/ARB adherence from an MoI telephonic intervention performed among nonadherent patients. Identifying specific barriers for patients may help to further design tailored interventions that address the barriers and improve adherence. CI - (c) 2022 Majd et al. FAU - Majd, Zahra AU - Majd Z AD - Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, USA. FAU - Mohan, Anjana AU - Mohan A AD - Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, USA. FAU - Johnson, Michael L AU - Johnson ML AD - Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, USA. FAU - Essien, Ekere J AU - Essien EJ AUID- ORCID: 0000-0001-8157-8290 AD - Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, USA. FAU - Barner, Jamie C AU - Barner JC AUID- ORCID: 0000-0002-6078-8093 AD - Health Outcomes Division, The University of Texas at Austin, Austin, TX, USA. FAU - Serna, Omar AU - Serna O AD - CareAllies, Houston, TX, USA. FAU - Gallardo, Esteban AU - Gallardo E AD - CareAllies, Houston, TX, USA. FAU - Fleming, Marc L AU - Fleming ML AD - Department of Pharmaceutical Economics and Policy, Chapman University School of Pharmacy, Irvine, CA, USA. FAU - Ordonez, Nancy AU - Ordonez N AD - Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA. FAU - Holstad, Marcia M AU - Holstad MM AUID- ORCID: 0000-0002-5558-8660 AD - Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, USA. FAU - Abughosh, Susan M AU - Abughosh SM AD - Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, USA. LA - eng GR - R15 HL135700/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20221004 PL - New Zealand TA - Patient Prefer Adherence JT - Patient preference and adherence JID - 101475748 PMC - PMC9547592 OTO - NOTNLM OT - adherence barriers OT - angiotensin converting enzyme inhibitors OT - angiotensin receptor blockers OT - group-based trajectory modeling OT - motivational interviewing OT - polypharmacy COIS- Dr. Abughosh reports grants from NIH, during the conduct of the study and grants from CARsgen and Valeant Pharmaceuticals, outside the submitted work. Dr. Barner reports grants from NIH and personal fees from University of Houston, during the conduct of the study and grants from Centers for Disease Control, Texas Health and Human Services, and Pharmaceutical Research Manufacturers of America Foundation, outside the submitted work. Dr. Fleming reports grants from National Heart, Lung, and Blood Institute and National Institute on Minority Health and Health Disparities (U-54). Dr. Fleming also reports contracts from Texas Health and Human Services Commission and CoI funding on a grant from Texas Council for Developmental Disabilities, outside the submitted work. Dr. Gallardo is an employee of CareAllies, a subsidiary of Cigna, outside of the submitted work. The authors report no other potential conflicts of interest for this work. EDAT- 2022/10/12 06:00 MHDA- 2022/10/12 06:01 PMCR- 2022/10/04 CRDT- 2022/10/11 01:45 PHST- 2022/02/03 00:00 [received] PHST- 2022/07/15 00:00 [accepted] PHST- 2022/10/11 01:45 [entrez] PHST- 2022/10/12 06:00 [pubmed] PHST- 2022/10/12 06:01 [medline] PHST- 2022/10/04 00:00 [pmc-release] AID - 360461 [pii] AID - 10.2147/PPA.S360461 [doi] PST - epublish SO - Patient Prefer Adherence. 2022 Oct 4;16:2739-2748. doi: 10.2147/PPA.S360461. eCollection 2022.